2. Academic Validation
  3. Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer

Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer

  • J Med Chem. 2026 Feb 26;69(4):4548-4566. doi: 10.1021/acs.jmedchem.5c03208.
James Neef 1,  Kimberly S Straley 1,  Chinmoy Mukherjee 2,  Amol Tipnis 2,  Suleman Riyajsaheb Maujan 2,  Maulasri Bhatta 1,  Sambad Sharma 1,  Sara Sinicropi-Yao 1,  Joe DeBartolo 1,  Andrew J McRiner 1,  Betty Chan 1,  Henry Wilson 1,  Christina S Lee 1,  Zied Boudhraa 3,  Mohamed El Ezzy 3,  Mark Bittinger 1,  Laura Jennings Antipov 1,  Thomas G Graeber 1,  Katharine E Yen 1,  David S Millan 1
Affiliations

Affiliations

  • 1 Auron Therapeutics, Newton Massachusetts 02458 United States.
  • 2 Medicinal Chemistry Department, Sai Life Sciences Limited, DS-7, ICICI Knowledge Park, Shameerpet, Hyderabad 500 078 Telangana, India.
  • 3 Paraza Pharma, Inc, 275 Boul. Armand-Frappier Laval, QC H7 V 4A Canada.
PMID: 41656736 DOI: 10.1021/acs.jmedchem.5c03208
Abstract

Using our proprietary AI/ML platform AURIGIN that maps tumor cells against normal developmental pathways, we identify targets that have been hijacked by cancerous cells to maintain a highly plastic proliferative cell state. We identified the Histone Acetyltransferase KAT2A as a key driver of tumor cell plasticity in a subset of acute myeloid leukemias (AML) and neuroendocrine carcinomas such as small cell lung Cancer (SCLC) and neuroendocrine prostate Cancer (NEPC). Herein, we describe our development of heterobifunctional degraders of KAT2A/B, resulting in compound 7, a picomolar degrader that is capable of inhibiting proliferation of AML (MOLM-13) and SCLC (NCI-H1048) cell lines in vitro and demonstrates robust degradation of KAT2A in NCI-H1048 engrafted mice when administered IP. Building on the success of compound 7, we subsequently developed orally bioavailable degraders of KAT2A/B, exemplified by compound 24, that achieved an oral bioavailability of 47% in mice.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z